Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches

Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company.

This agreement will build upon the existing collaboration to evaluate the potential of using Optimer-based strategies to target renal cells and explore the feasibility of developing next-generation drug delivery vehicles, Optimer-drug conjugates.   

Optimers are optimized aptamer reagents. Based on oligonucleotide molecules Optimers can bind specifically to a target molecule to act as an antibody alternative. Their ability to fold into distinct secondary or tertiary structures gives them high affinity and specific binding toward cell-specific targets. They are emerging as promising alternatives in a range of applications.

This extension will further unite Aptamer Group’s expertise and knowledge in the development of aptamer-based technologies with AstraZeneca’s leadership in Cardiovascular, Renal and Metabolism (CVRM) therapy development.

Arron Tolley, CEO of Aptamer Group said “We are really pleased to continue the collaboration with AstraZeneca. We believe that our platform technology could be transformational in the development of drug delivery vehicles. Through working with AstraZeneca, we can explore the potential of these new modalities in the early-stage drug development process”.

Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca said “Oligonucleotide conjugates offer the potential to reach a specific cell or tissue, and have the potential to have a real impact for new drug targets identified in renal disease. By working together with Aptamer Group and leveraging their Optimer-based strategies we aim to identify novel targeting aptamers to deliver drug molecules to the kidney.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Aptamer Group. (2021, March 05). Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches. News-Medical. Retrieved on December 02, 2021 from https://www.news-medical.net/news/20210305/Aptamer-Group-Extends-Collaboration-With-Leading-Biopharmaceutical-Company-to-Explore-Next-Generation-Drug-Delivery-Approaches.aspx.

  • MLA

    Aptamer Group. "Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches". News-Medical. 02 December 2021. <https://www.news-medical.net/news/20210305/Aptamer-Group-Extends-Collaboration-With-Leading-Biopharmaceutical-Company-to-Explore-Next-Generation-Drug-Delivery-Approaches.aspx>.

  • Chicago

    Aptamer Group. "Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches". News-Medical. https://www.news-medical.net/news/20210305/Aptamer-Group-Extends-Collaboration-With-Leading-Biopharmaceutical-Company-to-Explore-Next-Generation-Drug-Delivery-Approaches.aspx. (accessed December 02, 2021).

  • Harvard

    Aptamer Group. 2021. Aptamer Group Extends Collaboration With Leading Biopharmaceutical Company to Explore Next-Generation Drug Delivery Approaches. News-Medical, viewed 02 December 2021, https://www.news-medical.net/news/20210305/Aptamer-Group-Extends-Collaboration-With-Leading-Biopharmaceutical-Company-to-Explore-Next-Generation-Drug-Delivery-Approaches.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test